RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
about
Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerVandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Cabozantinib in progressive medullary thyroid cancer.Solid tumors associated with multiple endocrine neoplasias.Endocrine side effects of broad-acting kinase inhibitors.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.Modeling thyroid cancer in the mouse.Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.p27kip1: a new multiple endocrine neoplasia gene?Vandetanib for the treatment of metastatic medullary thyroid cancerDemonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells.Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.Genetic and Epigenetic of Medullary Thyroid Cancer.Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates
P2860
Q27005701-D6EF6C37-3CCF-45F6-A84B-C96D2205F7C3Q34131012-34928589-13B8-4625-A07B-EF0DBB079BD8Q34185084-4C11C9B8-6DEC-469B-AC6C-309A1D503DF8Q34213017-5C63D54C-4CCA-4ED3-8BBC-6A34C415622BQ34574985-E9D35EE2-4097-48C3-A180-1455A1907577Q34758477-C89CCD93-6E91-4764-B088-E5B0C278EC33Q35087767-159CDFA8-B5B8-408C-8BFC-375FD4040064Q35755355-906C1F36-D81E-44E3-99E6-51A3997A1C9FQ36068707-AA29B3FC-97B0-49DD-A798-86DE7E9F2BD9Q36297044-C11F2FBA-85CE-4B9E-B10F-570CADD7A142Q36520616-02A55C25-0D5C-4115-B498-C2A36F9E22FAQ37403891-0F49C05A-06AB-4E21-A518-348B54CCAA97Q37803487-593602C0-F5A8-4A75-8198-7B0BC9693B94Q38020834-5D30AD5D-97BB-4900-8B81-BEC61933E53FQ38703728-F30D75FB-F97A-4322-9DE6-F87EAD660EBCQ39012303-280194B0-CB28-4A38-9D2E-76E3FD948729Q39036145-027C2203-CF87-4211-AE36-86175DA77BE2Q41251561-E3C492B6-C89B-4CCD-8A91-536383584176Q45998322-CCA4447F-484E-4D05-AE95-7F8327BC5A9AQ52984965-B980F367-957B-4482-8021-B53C4F3CDAB0Q55008552-B22C7FF7-7B20-4927-B703-A999E979AB7FQ58796314-41463C70-447B-4751-9C5B-E91216F7ABD4
P2860
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@en
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@nl
type
label
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@en
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@nl
prefLabel
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@en
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@nl
P2860
P356
P1476
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
@en
P2093
Maya B Lodish
P2860
P304
P356
10.1586/14737140.8.4.625
P577
2008-04-01T00:00:00Z